Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication
Elazar, M., Cheong, K. H., Liu, P., Greenberg, H. B., Rice, C. M., & Glenn, J. S. (2003). Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. JOURNAL OF VIROLOGY, 77(10), 6055–61.

In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus
Bordier, B. B., Ohkanda, J., Liu, P., Lee, S. Y., Salazar, F. H., Marion, P. L., … Glenn, J. S. (2003). In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. JOURNAL OF CLINICAL INVESTIGATION, 112(3), 407–14.

Prenylation inhibitors: a novel class of antiviral agents
Einav, S., & Glenn, J. S. (2003). Prenylation inhibitors: a novel class of antiviral agents. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 52(6), 883–86.

Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitors.
Bordier, B. B., & Glenn, J. S. (2004). Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitors. Methods in Molecular Medicine, 96, 539–53.

Overdependence on the host-an Achilles' heel of HCV?
Glenn, J. S. (2004). Overdependence on the host-an Achilles' heel of HCV? Hepatology , 39(6), 1734–35.

A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication
Einav, S., Elazar, M., Danieli, T., & Glenn, J. S. (2004). A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. JOURNAL OF VIROLOGY, 78(20), 11288–95.

An n-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication
Elazar, M., Liu, P., Rice, C. M., & Glenn, J. S. (2004). An n-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. JOURNAL OF VIROLOGY, 78(20), 11393–400.

Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts
Matto, M., Rice, C. M., Aroeti, B., & Glenn, J. S. (2004). Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts. JOURNAL OF VIROLOGY, 78(21), 12047–53.

IDENTIFICATION OF A PRENYLATION SITE IN DELTA-VIRUS LARGE ANTIGEN
Glenn, J. S., Watson, J. A., HAVEL, C. M., & White, J. M. (1992). IDENTIFICATION OF A PRENYLATION SITE IN DELTA-VIRUS LARGE ANTIGEN. SCIENCE, 256(5061), 1331–1333.

Molecular virology of the hepatitis C virus: implication for novel therapies.
Glenn, J. S. (2005). Molecular virology of the hepatitis C virus: implication for novel therapies. Clinics in Liver Disease, 9(3), 353-?

Novel therapies for hepatitis C virus based on lessons from virology.
Glenn, J. S. (2005). Novel therapies for hepatitis C virus based on lessons from virology. Clinical Gastroenterology and Hepatology , 3(10), S86–8.

Molecular virology of the hepatitis C virus: Implication for novel therapies
Glenn, J. S. (2006). Molecular virology of the hepatitis C virus: Implication for novel therapies. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 20(1), 81-?

Prenylation of HDAg and antiviral drug development
Glenn, J. S. (2006). Prenylation of HDAg and antiviral drug development. HEPATITIS DELTA VIRUS, 307, 133–149.

Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes
Cho, N.-J., Cheong, K. H., Lee, C., Frank, C. W., & Glenn, J. S. (2007). Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes. JOURNAL OF VIROLOGY, 81(12), 6682–89.

The power of silence: Application of small interfering RNAs to gastrointestinal diseases
Sklan, E. H., & Glenn, J. S. (2007). The power of silence: Application of small interfering RNAs to gastrointestinal diseases. GASTROENTEROLOGY, 132(7), 2291–95.

Employing an amphipathic viral peptide to create a lipid bilayer on Au and TiO2
Cho, N.-J., Cho, S.-J., Cheong, K. H., Glenn, J. S., & Frank, C. W. (2007). Employing an amphipathic viral peptide to create a lipid bilayer on Au and TiO2. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 129(33), 10050-?

Employing two different quartz crystal microbalance models to study changes in viscoelastic behavior upon transformation of lipid vesicles to a bilayer on a gold surface
Chot, N.-J., Kanazawa, K. K., Glenn, J. S., & Frank, C. W. (2007). Employing two different quartz crystal microbalance models to study changes in viscoelastic behavior upon transformation of lipid vesicles to a bilayer on a gold surface. ANALYTICAL CHEMISTRY, 79(18), 7027–35.

A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication
Sklan, E. H., Staschke, K., Oakes, T. M., Elazar, M., Winters, M., Aroeti, B., … Glenn, J. S. (2007). A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication. JOURNAL OF VIROLOGY, 81(20), 11096–105.

Creation of lipid partitions by deposition of amphipathic viral peptides
Cho, N.-J., Cho, S.-J., Hardesty, J. O., Glenn, J. S., & Frank, C. W. (2007). Creation of lipid partitions by deposition of amphipathic viral peptides. LANGMUIR, 23(21), 10855–63.

TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication
Sklan, E. H., Serrano, R. L., Einav, S., Pfeffer, S. R., Lambright, D. G., & Glenn, J. S. (2007). TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication. JOURNAL OF BIOLOGICAL CHEMISTRY, 282(50), 36354–61.

The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without ha-ras co-transfection
Einav, S., Sklan, E. H., Moon, H. M., Gehrig, E., Liu, P., Hao, Y., … Glenn, J. S. (2008). The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without ha-ras co-transfection. HEPATOLOGY, 47(3), 827–35.

Hepatitis d.
Koytak, E. S., Yurdaydin, C., & Glenn, J. S. (2007). Hepatitis d. Current Treatment Options in Gastroenterology, 10(6), 456–63.

A drug-controllable tag for visualizing newly synthesized proteins in cells and whole animals
Lin, M. Z., Glenn, J. S., & Tsien, R. Y. (2008). A drug-controllable tag for visualizing newly synthesized proteins in cells and whole animals. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(22), 7744–49.

Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cells
Chiao, E., Elazar, M., Xing, Y., Xiong, A., Kmet, M., Millan, M. T., … Baker, J. (2008). Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cells. STEM CELLS, 26(8), 2032–41.

Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide
Korba, B. E., Elazar, M., Lui, P., Rossignol, J.-F., & Glenn, J. S. (2008). Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4069–71.

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis
Einav, S., Gerber, D., Bryson, P. D., Sklan, E. H., Elazar, M., Maerkl, S. J., … Quake, S. R. (2008). Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. NATURE BIOTECHNOLOGY, 26(9), 1019–27.

Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel
Cho, N.-J., Elazar, M., Xiong, A., Lee, W., Chiao, E., Baker, J., … Glenn, J. S. (2009). Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel. BIOMEDICAL MATERIALS, 4(1).

Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells
Xiong, A., Austin, T. W., Lagasse, E., Uchida, N., Tamaki, S., Bordier, B. B., … Millan, M. T. (2008). Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells. TISSUE ENGINEERING PART A, 14(6), 995–1006.

Mechanisms of HCV survival in the host
Sklan, E. H., Charuworn, P., Pang, P. S., & Glenn, J. S. (2009). Mechanisms of HCV survival in the host. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 6(4), 217–27.

Alpha-Helical Peptide-Induced Vesicle Rupture Revealing New Insight into the Vesicle Fusion Process As Monitored in Situ by Quartz Crystal Microbalance-Dissipation and Reflectometry
Cho, N.-J., Wang, G., Edvardsson, M., Glenn, J. S., Hook, F., & Frank, C. W. (2009). Alpha-Helical Peptide-Induced Vesicle Rupture Revealing New Insight into the Vesicle Fusion Process As Monitored in Situ by Quartz Crystal Microbalance-Dissipation and Reflectometry. ANALYTICAL CHEMISTRY, 81(12), 4752–61.

The Anti-Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2 alpha Via Protein Kinase Activated by Double-Stranded RNA Activation
Elazar, M., Liu, M., Mckenna, S. A., Liu, P., Gehrig, E. A., Puglisi, J. D., … Glenn, J. S. (2009). The Anti-Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2 alpha Via Protein Kinase Activated by Double-Stranded RNA Activation. GASTROENTEROLOGY, 137(5), 1827–35.

The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy
Pang, P. S., Planet, P. J., & Glenn, J. S. (2009). The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy. PLOS ONE, 4(8).

The Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C
Pang, P. S., Kamal, A., & Glenn, J. S. (2009). The Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C. LIVER TRANSPLANTATION, 15(9), 1126–32.

The reliable targeting of specific drug release profiles by integrating arrays of different albumin-encapsulated microsphere types
Lee, W., Wiseman, M. E., Cho, N.-J., Glenn, J. S., & Frank, C. W. (2009). The reliable targeting of specific drug release profiles by integrating arrays of different albumin-encapsulated microsphere types. BIOMATERIALS, 30(34), 6648–54.

Mechanism of an Amphipathic alpha-Helical Peptide's Antiviral Activity Involves Size-Dependent Virus Particle Lysis
Cho, N.-J., Dvory-Sobol, H., Xiong, A., Cho, S.-J., Frank, C. W., & Glenn, J. S. (2009). Mechanism of an Amphipathic alpha-Helical Peptide's Antiviral Activity Involves Size-Dependent Virus Particle Lysis. ACS CHEMICAL BIOLOGY, 4(12), 1061–67.

Six RNA Viruses and Forty-One Hosts: Viral Small RNAs and Modulation of Small RNA Repertoires in Vertebrate and Invertebrate Systems
Parameswaran, P., Sklan, E., Wilkins, C., Burgon, T., Samuel, M. A., Lu, R., … Fire, A. Z. (2010). Six RNA Viruses and Forty-One Hosts: Viral Small RNAs and Modulation of Small RNA Repertoires in Vertebrate and Invertebrate Systems. PLOS PATHOGENS, 6(2).

Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach
Lue, J., Lin, G., Ning, H., Xiong, A., Lin, C.-S., & Glenn, J. S. (2010). Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach. LIVER INTERNATIONAL, 30(6), 913–22.

A small molecule inhibits HCV replication and alters NS4B's subcellular distribution
Bryson, P. D., Cho, N.-J., Einav, S., Lee, C., Tai, V., Bechtel, J., … Glenn, J. S. (2010). A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. ANTIVIRAL RESEARCH, 87(1), 1–8.

Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B
Cho, N.-J., Dvory-Sobol, H., Lee, C., Cho, S.-J., Bryson, P., Masek, M., … Glenn, J. S. (2010). Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B. SCIENCE TRANSLATIONAL MEDICINE, 2(15).

The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors.
Einav, S., Sobol, H. D., Gehrig, E., & Glenn, J. S. (2010). The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. Journal of Infectious Diseases, 202(1), 65–74.

Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users
Kucirka, L. M., Farzadegan, H., Feld, J. J., Mehta, S. H., Winters, M., Glenn, J. S., … Golub, E. T. (2010). Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users. JOURNAL OF INFECTIOUS DISEASES, 202(6), 845–52.

Role for ADP Ribosylation Factor 1 in the Regulation of Hepatitis C Virus Replication
Matto, M., Sklan, E. H., David, N., Melamed-Book, N., Casanova, J. E., Glenn, J. S., & Aroeti, B. (2011). Role for ADP Ribosylation Factor 1 in the Regulation of Hepatitis C Virus Replication. JOURNAL OF VIROLOGY, 85(2), 946–56.

Hydrophobic nanoparticles improve permeability of cell-encapsulating poly(ethylene glycol) hydrogels while maintaining patternability
Lee, W., Cho, N.-J., Xiong, A., Glenn, J. S., & Frank, C. W. (2010). Hydrophobic nanoparticles improve permeability of cell-encapsulating poly(ethylene glycol) hydrogels while maintaining patternability. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 107(48), 20709–14.

Mixing the right hepatitis C inhibitor cocktail.
Gelman, M. A., & Glenn, J. S. (2010). Mixing the right hepatitis C inhibitor cocktail. Trends in Molecular Medicine.

The Future of HCV Therapy: NS4B as an Antiviral Target
Dvory-Sobol, H., Pang, P. S., & Glenn, J. S. (2010). The Future of HCV Therapy: NS4B as an Antiviral Target. VIRUSES-BASEL, 2(11), 2481–92.

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein
Lee, C., Ma, H., Hang, J. Q., Leveque, V., Sklan, E. H., Elazar, M., … Glenn, J. S. (2011). The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. VIROLOGY, 414(1), 10–18.

Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons
Thomas, C., Moraga, I., Levin, D., Krutzik, P. O., Podoplelova, Y., Trejo, A., … Garcia, K. C. (2011). Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons. CELL, 146(4), 621–32.

Simplified RNA secondary structure mapping by automation of SHAPE data analysis
Pang, P. S., Elazar, M., Pham, E. A., & Glenn, J. S. (2011). Simplified RNA secondary structure mapping by automation of SHAPE data analysis. NUCLEIC ACIDS RESEARCH, 39(22).

Structural Map of a MicroRNA-122: Hepatitis C Virus Complex
Pang, P. S., Pham, E. A., Elazar, M., Patel, S. G., Eckart, M. R., & Glenn, J. S. (2012). Structural Map of a MicroRNA-122: Hepatitis C Virus Complex. JOURNAL OF VIROLOGY, 86(2), 1250–54.

Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction
Nishimura, T., Hu, Y., Wu, M., Pham, E., Suemizu, H., Elazar, M., … Peltz, G. (2013). Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 344(2), 388–96.

The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA.
Lisowski, L., Elazar, M., Chu, K., Glenn, J. S., & Kay, M. A. (2013). The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. Nucleic Acids Research, 41(6), 3688–98.

Finding the iron in the melting pot - Practical use of a new genetic assay for hereditary hemochromatosis
Glenn, J. S., & Cheung, R. C. (1998). Finding the iron in the melting pot - Practical use of a new genetic assay for hereditary hemochromatosis. WESTERN JOURNAL OF MEDICINE, 168(6), 525–527.

Use of a prenylation inhibitor as a novel antiviral agent
Glenn, J. S., Marsters, J. C., & Greenberg, H. B. (1998). Use of a prenylation inhibitor as a novel antiviral agent. JOURNAL OF VIROLOGY, 72(11), 9303–6.

Shutting the door on hepatitis delta virus (HDV): Sensitivity to prenylation inhibition prompts new therapeutic strategy
Shutting the door on hepatitis delta virus (HDV): Sensitivity to prenylation inhibition prompts new therapeutic strategy. (1999). Viral Hepatitis Reviews, 53.

BINDING DYNAMICS OF HEPATITIS C VIRUS' NONSTRUCTURAL PROTEINS TO CELL AND MODEL MEMBRANES
Cho, N.-J., Frank, C. W., & Glenn, J. S. (2008). BINDING DYNAMICS OF HEPATITIS C VIRUS' NONSTRUCTURAL PROTEINS TO CELL AND MODEL MEMBRANES. HEPATOLOGY, 48(4), 758A–759A.

STRUCTURAL INSIGHTS INTO THE MECHANISM OF MICRORNA-MODULATED HCV TRANSLATION
Pang, P. S., Pham, E. A., Patel, S. G., Winters, M. A., Eckart, M. R., & Glenn, J. S. (2010). STRUCTURAL INSIGHTS INTO THE MECHANISM OF MICRORNA-MODULATED HCV TRANSLATION. HEPATOLOGY. BOSTON,MA,MA,MA,MA,MA,MA,MA: WILEY-BLACKWELL.

PHARMACOLOGICAL INHIBITORS OF A NEW HEPATITIS C TARGET-RNA BINDING BY NS4B-DISCOVERED BY MICROFLUIDIC AFFINITY ANALYSIS
Einav, S., Gerber, D., Bryson, P. D., Sklan, E., Elazar, M., Maerkl, S., … Glenn, J. S. (2008). PHARMACOLOGICAL INHIBITORS OF A NEW HEPATITIS C TARGET-RNA BINDING BY NS4B-DISCOVERED BY MICROFLUIDIC AFFINITY ANALYSIS. HEPATOLOGY, 48(4), 356A–356A.

Mixing the right hepatitis C inhibitor cocktail
Gelman, M. A., & Glenn, J. S. (2011). Mixing the right hepatitis C inhibitor cocktail. TRENDS IN MOLECULAR MEDICINE, 17(1), 34–46.

THE EVOLUTION OF HEPATITIS C VIRUS INNATE IMMUNE EVASION
Pang, P. S., Planet, P. J., Pham, E. A., & Glenn, J. S. (2010). THE EVOLUTION OF HEPATITIS C VIRUS INNATE IMMUNE EVASION. JOURNAL OF INVESTIGATIVE MEDICINE, 58(1), 180–80.

An HCV IRES element regulates viral replication independent of translation
Pham, E. A., Cho, N.-J., Pang, P. S., Leveque, V. J., Ma, H., Klumpp, K., & Glenn, J. (2012). An HCV IRES element regulates viral replication independent of translation. Presented at the 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), BOSTON,MA,MA,MA,MA,MA,MA,MA: WILEY-BLACKWELL.

Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity
Lasheen, D. S., Ismail, M. A. H., Abou El Ella, D. A., Ismail, N. S. M., Eid, S., Vleck, S., … Abouzid, K. A. M. (2013). Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity. BIOORGANIC & MEDICINAL CHEMISTRY, 21(10), 2742–55.

Studies of the potential for resistance to nitazoxanide or tizoxanide
Korba, B. E., Glenn, J. S., Ayers, M. S., & Rossignol, J. F. (2008). Studies of the potential for resistance to nitazoxanide or tizoxanide. Presented at the 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, MILAN,ITALY,ITALY: ELSEVIER SCIENCE BV.

NITAZOXANIDE (NTZ) IS AN INDUCER EIF2A AND PKR PHOSPHORYLATION
Elazor, M., Liu, M., McKenna, S., Liu, P., Gehrig, E. A., Elfert, A., … Glenn, J. S. (2008). NITAZOXANIDE (NTZ) IS AN INDUCER EIF2A AND PKR PHOSPHORYLATION. HEPATOLOGY. SAN FRANCISCO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: WILEY-BLACKWELL.

Using 'Humanized' TK-NOG mice to predict human drug metabolism and drug-drug interactions
Hu, Y., Nishimura, T., Wu, M., Suemizu, H., Elazar, M., Glenn, J., … Peltz, G. (2011). Using 'Humanized' TK-NOG mice to predict human drug metabolism and drug-drug interactions. Presented at the 17th North American Regional International-Society-for-the-Study-of-Xenobiotics (ISSX) Meeting, ATLANTA,GA,GA,GA,GA,GA,GA,GA,GA,GA,GA,GA,GA: INFORMA HEALTHCARE.

Development of novel therapies for hepatitis C
Lemon, S. M., McKeating, J. A., Pietschmann, T., Frick, D. N., Glenn, J. S., Tellinghuisen, T. L., … Furman, P. A. (2010). Development of novel therapies for hepatitis C. ANTIVIRAL RESEARCH, 86(1), 79–92.

The stanford institute for chemical biology.
Chen, J. K., Du Bois, J., Glenn, J., Herschlag, D., & Khosla, C. (2013). The stanford institute for chemical biology. ACS Chemical Biology, 8(9), 1860–61.

Coinfection with hepatitis B and D: Epidemiology, prevalence and disease in patients in Northern California
Gish, R. G., Yi, D. H., Kane, S., Clark, M., Mangahas, M., Baqai, S., … Glenn, J. S. (2013). Coinfection with hepatitis B and D: Epidemiology, prevalence and disease in patients in Northern California. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28(9), 1521–25.

Enabling Autologous Human Liver Regeneration With Differentiated Adipocyte Stem Cells
Xu, D., Nishimura, T., Zheng, M., Wu, M., Su, H., Sato, N., … Peltz, G. (2014). Enabling Autologous Human Liver Regeneration With Differentiated Adipocyte Stem Cells. CELL TRANSPLANTATION, 23(12), 1573–84.

Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing.
Xu, D., Nishimura, T., Nishimura, S., Zhang, H., Zheng, M., Guo, Y.-Y., … Peltz, G. (2014). Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Medicine, 11(4).

Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing.
Xu, D., Nishimura, T., Nishimura, S., Zhang, H., Zheng, M., Guo, Y.-Y., … Peltz, G. (2014). Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing. PLoS Medicine, 11(4).

The interaction between the Hepatitis C proteins NS4B and NS5A is involved in viral replication.
David, N., Yaffe, Y., Hagoel, L., Elazar, M., Glenn, J. S., Hirschberg, K., & Sklan, E. H. (2015). The interaction between the Hepatitis C proteins NS4B and NS5A is involved in viral replication. Virology, 475, 139–49.

Phosphatidylinositol 4,5-Bisphosphate Is an HCV NS5A Ligand and Mediates Replication of the Viral Genome.
Cho, N.-J., Lee, C., Pang, P. S., Pham, E. A., Fram, B., Nguyen, K., … Glenn, J. S. (2015). Phosphatidylinositol 4,5-Bisphosphate Is an HCV NS5A Ligand and Mediates Replication of the Viral Genome. Gastroenterology, 148(3), 616–25.

Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis
Perumpail, R. B., Wong, R. J., Ha, L. D., Pham, E. A., Wang, U., Luong, H., … Ahmed, A. (2015). Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. TRANSPLANT INFECTIOUS DISEASE, 17(2), 275–78.

TRANSDOMINANT INHIBITION OF HUMAN HEPATITIS-DELTA VIRUS GENOME REPLICATION
Glenn, J. S., & White, J. M. (1991). TRANSDOMINANT INHIBITION OF HUMAN HEPATITIS-DELTA VIRUS GENOME REPLICATION. JOURNAL OF VIROLOGY, 65(5), 2357–61.

DELIVERY OF MACROMOLECULES INTO CELLS EXPRESSING A VIRAL MEMBRANE-FUSION PROTEIN
Ellens, H., Doxsey, S., Glenn, J. S., & White, J. M. (1989). DELIVERY OF MACROMOLECULES INTO CELLS EXPRESSING A VIRAL MEMBRANE-FUSION PROTEIN. METHODS IN CELL BIOLOGY, 31, 155–76.

DELIVERY OF LIPOSOME-ENCAPSULATED RNA TO CELLS EXPRESSING INFLUENZA-VIRUS HEMAGGLUTININ
Glenn, J. S., Ellens, H., & White, J. M. (1993). DELIVERY OF LIPOSOME-ENCAPSULATED RNA TO CELLS EXPRESSING INFLUENZA-VIRUS HEMAGGLUTININ. METHODS IN ENZYMOLOGY, 221, 327–39.

REPLICATION OF MONOMERIC GENOMIC-DELTA RNA IN CULTURED-CELLS
Glenn, J. S., Taylor, J., & White, J. M. (1991). REPLICATION OF MONOMERIC GENOMIC-DELTA RNA IN CULTURED-CELLS. Presented at the 3RD INTERNATIONAL SYMP ON HEPATITIS DELTA VIRUS, WASHINGTON,DC,DC: WILEY-LISS, INC.

Hepatitis D in Children
Xue, M. M., Glenn, J. S., & Leung, D. H. (2015). Hepatitis D in Children. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 61(3), 271–81.

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
Koh, C., Canini, L., Dahari, H., Zhao, X., Uprichard, S. L., Haynes-Williams, V., … Heller, T. (2015). Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. LANCET INFECTIOUS DISEASES, 15(10), 1167–74.

Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase III beta
Rutaganira, F. U., Fowler, M. L., McPhail, J. A., Gelman, M. A., Nguyen, K., Xiong, A., … Burke, J. E. (2016). Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase III beta. JOURNAL OF MEDICINAL CHEMISTRY, 59(5), 1830–39.

Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification
Deans, R. M., Morgens, D. W., Okesli, A., Pillay, S., Horlbeck, M. A., Kampmann, M., … Bassik, M. C. (2016). Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. NATURE CHEMICAL BIOLOGY, 12(5), 361-?

Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIß.
Rutaganira, F. U., Fowler, M. L., McPhail, J. A., Gelman, M. A., Nguyen, K., Xiong, A., … Burke, J. E. (2016). Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIß. Journal of Medicinal Chemistry, 59(5), 1830–39.

Multistep Compositional Remodeling of Supported Lipid Membranes by Interfacially Active Phosphatidylinositol Kinases
Tabaei, S. R., Guo, F., Rutaganira, F. U., Vafaei, S., Choong, I., Shokat, K. M., … Cho, N.-J. (2016). Multistep Compositional Remodeling of Supported Lipid Membranes by Interfacially Active Phosphatidylinositol Kinases. ANALYTICAL CHEMISTRY, 88(10), 5042–45.

Reconstitution and Functional Analysis of a Full-Length Hepatitis C Virus NS5B Polymerase on a Supported Lipid Bilayer.
Cho, N.-J., Pham, E. A., Hagey, R. J., Lévêque, V. J., Ma, H., Klumpp, K., & Glenn, J. S. (2016). Reconstitution and Functional Analysis of a Full-Length Hepatitis C Virus NS5B Polymerase on a Supported Lipid Bilayer. ACS Central Science, 2(7), 456–66.

The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease Inhibitors
Einav, S., Dvory-Sobol, H., Gehrig, E., & Glenn, J. S. (2010). The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease Inhibitors. JOURNAL OF INFECTIOUS DISEASES, 202(1), 65–74.

The IFN-?-IFN-?R1-IL-10Rß Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.
Mendoza, J. L., Schneider, W. M., Hoffmann, H.-H., Vercauteren, K., Jude, K. M., Xiong, A., … Garcia, K. C. (2017). The IFN-?-IFN-?R1-IL-10Rß Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity. Immunity, 46(3), 379–92.

Extracellular Matrix Functionalization and Huh-7.5 Cell Coculture Promote the Hepatic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells in a 3D ICC Hydrogel Scaffold
Wang, Y., Lee, J.-H., Shirahama, H., Seo, J., Glenn, J. S., & Cho, N.-J. (2016). Extracellular Matrix Functionalization and Huh-7.5 Cell Coculture Promote the Hepatic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells in a 3D ICC Hydrogel Scaffold. ACS BIOMATERIALS SCIENCE & ENGINEERING, 2(12), 2255–65.

Future Therapy for Hepatitis B Virus: Role of Immunomodulators.
Pham, E. A., Perumpail, R. B., Fram, B. J., Glenn, J. S., Ahmed, A., & Gish, R. G. (2016). Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Current Hepatology Reports, 15(4), 237–44.

ECM proteins in a microporous scaffold influence hepatocyte morphology, function, and gene expression
Wang, Y., Kim, M. H., Shirahama, H., Lee, J. H., Ng, S. S., Glenn, J. S., & Cho, N.-J. (2016). ECM proteins in a microporous scaffold influence hepatocyte morphology, function, and gene expression. SCIENTIFIC REPORTS, 6.

A novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians.
Chen, X., Oidovsambuu, O., Liu, P., Grosely, R., Elazar, M., Winn, V. D., … Glenn, J. S. (2016). A novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians. Hepatology .

The IFN-lambda-IFN-lambda R1-IL-10R beta Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity
Mendoza, J. L., Schneider, W. M., Hoffmann, H.-H., Vercauteren, K., Jude, K. M., Xiong, A., … Garcia, K. C. (2017). The IFN-lambda-IFN-lambda R1-IL-10R beta Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity. IMMUNITY, 46(3), 379–92.

Emerging concepts for the treatment of hepatitis delta.
Elazar, M., & Glenn, J. S. (2017). Emerging concepts for the treatment of hepatitis delta. Current Opinion in Virology, 24, 55–59.

Long-term culture of human liver tissue with advanced hepatic functions.
Ng, S. S., Xiong, A., Nguyen, K., Masek, M., No, D. Y., Elazar, M., … Glenn, J. S. (2017). Long-term culture of human liver tissue with advanced hepatic functions. JCI Insight, 2(11).

Profiling system-wide immune signaling in chronic viral infection and its response to viral clearance
Angel, C. J. L., Furman, D., Pham, E., Fram, B., Thai Nguyen, Ahmed, A., … Davis, M. M. (2016). Profiling system-wide immune signaling in chronic viral infection and its response to viral clearance. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS.

IDENTIFICATION AND TARGETING OF VIRAL-HOST PROTEIN-PROTEIN INTERACTIONS USING A NOVEL MICROFLUIDICS AFFINITY ASSAY
Einav, S., Gerber, D., & Glenn, J. S. (2010). IDENTIFICATION AND TARGETING OF VIRAL-HOST PROTEIN-PROTEIN INTERACTIONS USING A NOVEL MICROFLUIDICS AFFINITY ASSAY. HEPATOLOGY, 52(4), 743A.

Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States.
Cholankeril, G., Li, A. A., Cholankeril, R., Toll, A. E., Glenn, J. S., & Ahmed, A. (2018). Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States. Journal of General Internal Medicine.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop
Block, T. M., Alter, H., Brown, N., Brownstein, A., Brosgart, C., Chang, K.-M., … Shetty, K. (2018). Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop. ANTIVIRAL RESEARCH, 150, 93–100.

A research agenda for curing chronic hepatitis B virus infection
Alter, H., Block, T., Brown, N., Brownstein, A., Brosgart, C., Chang, K.-M., … Zoulim, F. (2018). A research agenda for curing chronic hepatitis B virus infection. HEPATOLOGY, 67(3), 1127–31.

Structure of an engineered IFN-lambda/IFN-lambda R1/IL-10R beta complex provides insight into the functional dichotomy of type III versus type I IFNs
Mendoza, J. L., Schneider, W. M., Hoffman, H.-H., Vercauteren, K., Jude, K. M., Xiong, A., … Garcia, K. C. (2017). Structure of an engineered IFN-lambda/IFN-lambda R1/IL-10R beta complex provides insight into the functional dichotomy of type III versus type I IFNs. CYTOKINE, 100, 46.

Emerging Therapeutic Targets for Hepatitis Delta Virus Infection.
Glenn, J. S. (2018). Emerging Therapeutic Targets for Hepatitis Delta Virus Infection. Gastroenterology & Hepatology, 14(1), 47–49.

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus
Mahale, P., Glenn, J. S., & O'Brien, T. R. (2017). Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus. ANNALS OF INTERNAL MEDICINE, 167(10), 759–60.

Prevalence of hepatitis D viremia among injection drug users in San Francisco
Mahale, P., Aka, P. V., Chen, X., Liu, P., Wang, A. S., Tseng, F.-C., … O'Brien, T. (2017). Prevalence of hepatitis D viremia among injection drug users in San Francisco. HEPATOLOGY. WILEY.

Quantitative Evaluation of Viral Protein Binding to Phosphoinositide Receptors and Pharmacological Inhibition
Kim, S.-O., Jackman, J. A., Elazar, M., Cho, S.-J., Glenn, J. S., & Cho, N.-J. (2017). Quantitative Evaluation of Viral Protein Binding to Phosphoinositide Receptors and Pharmacological Inhibition. ANALYTICAL CHEMISTRY, 89(18), 9742–50.

Letter to the Editor regarding article "Emerging concepts for the treatment of hepatitis delta" [Menashe Elazar and Jeffrey S Glenn, Curr Opin Virol 24 (2017) 55-59] Reply
Elazar, M., & Glenn, J. (2018). Letter to the Editor regarding article "Emerging concepts for the treatment of hepatitis delta" [Menashe Elazar and Jeffrey S Glenn, Curr Opin Virol 24 (2017) 55-59] Reply. CURRENT OPINION IN VIROLOGY, 28, 169.

Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study
Yurdaydin, C., Keskin, O., Kalkan, C., Karakaya, F., Caliskan, A., Karatayli, E., … Glenn, J. S. (2018). Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. HEPATOLOGY, 67(4), 1224–36.

Modeling hepatitis delta virus dynamics during ritonavir boosted lonafarnib treatment-the LOWR HDV-3 study
Dubey, P., Koh, C., Surana, P., Uprichard, S. L., Han, M. A. T., Fryzek, N., … Dahari, H. (2017). Modeling hepatitis delta virus dynamics during ritonavir boosted lonafarnib treatment-the LOWR HDV-3 study. HEPATOLOGY, 66, 21A.

Hepatitis D Viremia Among Injection Drug Users in San Francisco
Mahale, P., Aka, P., Chen, X., Liu, P., Fram, B. J., Wang, A. S., … O'Brien, T. R. (2018). Hepatitis D Viremia Among Injection Drug Users in San Francisco. JOURNAL OF INFECTIOUS DISEASES, 217(12), 1902–6.

Changing Trends in Etiology-based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.
Kim, D., Li, A. A., Gadiparthi, C., Khan, M. A., Cholankeril, G., Glenn, J. S., & Ahmed, A. (2018). Changing Trends in Etiology-based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology.

Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.
Kim, D., Li, A. A., Perumpail, B. J., Gadiparthi, C., Kim, W., Cholankeril, G., … Ahmed, A. (2018). Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. Hepatology (Baltimore, Md.).

Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold.
Ng, S. S., Saeb-Parsy, K., Blackford, S. J., Segal, J. M., Serra, M. P., Horcas-Lopez, M., … Rashid, S. T. (2018). Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold. Biomaterials, 182, 299–311.

A SMALL MOLECULE INHIBITS HCV REPLICATION BY DISRUPTING NS4B LOCALIZATION
Bryson, P. D., Cho, N.-J., Einav, S., Lee, C., Tai, V., Bechtel, J., … Glenn, J. S. (2008). A SMALL MOLECULE INHIBITS HCV REPLICATION BY DISRUPTING NS4B LOCALIZATION. HEPATOLOGY, 48(4), 1167A.

A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection
Wang, Y., Glenn, J. S., Winters, M. A., Shen, L.-ping, Choong, I., Shi, Y.-lun, … Zhang, F.-jie. (2018). A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 92(2), 112–17.

Hepatitis delta infection - Current and new treatment options
Elazar, M., Koh, C., & Glenn, J. S. (2017). Hepatitis delta infection - Current and new treatment options. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 31(3), 321–27.

HCV NS5A Inhibitors: The Devil Is in the Details
Elazar, M., & Glenn, J. S. (2014). HCV NS5A Inhibitors: The Devil Is in the Details. GASTROENTEROLOGY, 147(2), 273–77.

The Anti-Genomic (Negative) Strand of Hepatitis C Virus Is Not Targetable by shRNA
Lisowski, L., Elazar, M., Chu, K., Glenn, J. S., & Kay, M. A. (2013). The Anti-Genomic (Negative) Strand of Hepatitis C Virus Is Not Targetable by shRNA. MOLECULAR THERAPY, 21, S75.

NOVEL ANTI-HCV THERAPY: SINGLE SHRNA TARGETING BOTH STRANDS OF HCV
Lisowski, L., Elazar, M., Chu, K., Glenn, J. S., & Kay, M. A. (2011). NOVEL ANTI-HCV THERAPY: SINGLE SHRNA TARGETING BOTH STRANDS OF HCV. JOURNAL OF GENE MEDICINE, 13(7-8), 418–19.

NS4B Targets and Inhibitors
Elazar, M., & Glenn, J. S. (2011). NS4B Targets and Inhibitors. HEPATITIS C: ANTIVIRAL DRUG DISCOVERY AND DEVELOPMENT, 257–69.

AAV Based RNAi Therapies To Treat and/or Prevent HCV in Animal Models
Lisowski, L., Elazar, M., Grompe, M., Glenn, J. S., & Kay, M. A. (2009). AAV Based RNAi Therapies To Treat and/or Prevent HCV in Animal Models. MOLECULAR THERAPY, 17, S14.

POTENTIAL ROLE FOR NITAZOXANIDE IN COMBINATION WITH STAT-C AGENTS FOR THE INHIBITION OF HCV REPLICATION WITHOUT THE DEVELOPMENT OF RESISTANCE
Korba, B., Elazar, M., Liu, P., Glenn, J. S., & Rossignol, J.-F. (2008). POTENTIAL ROLE FOR NITAZOXANIDE IN COMBINATION WITH STAT-C AGENTS FOR THE INHIBITION OF HCV REPLICATION WITHOUT THE DEVELOPMENT OF RESISTANCE. HEPATOLOGY, 48(4), 356A.

Pathogenesis of and New Therapies for Hepatitis D.
Koh, C., Heller, T., & Glenn, J. S. (2018). Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology.

Hepatitis D virus infection, cirrhosis, and hepatocellular carcinoma in The Gambia.
Mahale, P., Aka, P., Chen, X., Pfeiffer, R. M., Liu, P., Groover, S., … O'Brien, T. R. (2019). Hepatitis D virus infection, cirrhosis, and hepatocellular carcinoma in The Gambia. Journal of Viral Hepatitis.

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.
Townsend, E. C., Zhang, G. Y., Ali, R., Firke, M., Moon, M. S., Han, M. A., … Heller, T. (2019). The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. Journal of Gastroenterology and Hepatology.

A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRPalpha expression.
Myers, L. M., Tal, M. C., Torrez Dulgeroff, L. B., Carmody, A. B., Messer, R. J., Gulati, G., … Hasenkrug, K. J. (2019). A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRPalpha expression. Nature Communications, 10(1), 794.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.
Tsuge, M., Uchida, T., Walsh, K., Ishida, Y., Tateno, C., Kumar, U., … Chayama, K. (2019). Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. Viruses, 11(3).

Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4
Rossignol, J.-F., Elfert, A., El-Gohary, Y., Keeffe, E. B., & Glenn, J. (2007). Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. HEPATOLOGY, 46(4), 316A–317A.

A putative Rab GTPase-activating protein binds hepatitis C virus NS5A and mediates viral replication
Sklan, E. H., Staschke, K., Myers, T. M., & Glenn, J. S. (2006). A putative Rab GTPase-activating protein binds hepatitis C virus NS5A and mediates viral replication. HEPATOLOGY, 44(4), 692A.

Confronting New and Old Antiviral Threats: Broad Spectrum Potential of Prenylation Inhibitors
Elazar, M., & Glenn, J. S. (2005). Confronting New and Old Antiviral Threats: Broad Spectrum Potential of Prenylation Inhibitors. ANTIVIRAL DRUG DISCOVERY FOR EMERGING DISEASES AND BIOTERRORISM THREATS, 249–61.

Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection
Canini, L., Koh, C., Cotler, S. J., Uprichard, S. L., Winters, M. A., Han, M. A. T., … Dahari, H. (2017). Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection. HEPATOLOGY COMMUNICATIONS, 1(4), 288–92.

Characterization of HDV and HBV kinetics during acute co-infection and interferon-alpha treatment in uPA/SCID chimeric mice with humanized livers
Uchida, T., Walsh, K., Hiraga, N., Imamura, M., Koh, C., Glenn, J., … Chayama, K. (2016). Characterization of HDV and HBV kinetics during acute co-infection and interferon-alpha treatment in uPA/SCID chimeric mice with humanized livers. HEPATOLOGY, 64, 9A–10A.

Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis-Interim Results From The Lowr Hdv-2 Study
Yurdaydin, C., Idilman, R., Kalkan, C., Karakaya, F., Kartal, A. C., Keskin, O., … Glenn, J. (2016). Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis-Interim Results From The Lowr Hdv-2 Study. HEPATOLOGY, 64, 910A–911A.

The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis
Yurdaydin, C., Idilman, R., Kalkan, C., Karakaya, F., Kartal, A. C., Keskin, O., … Glenn, J. (2016). The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis. HEPATOLOGY, 64, 927A.

A Phase 2 Study Of Titrating-Dose Lonafarnib Plus Ritonavir In Patients With Chronic Hepatitis D: Interim Results From The Lonafarnib With Ritonavir In HDV-4 (LOWR HDV-4) Study
Wedemeyer, H., Port, K., Deterding, K., Wranke, A., Kirschner, J., Martins, E. B., … Manns, M. P. (2016). A Phase 2 Study Of Titrating-Dose Lonafarnib Plus Ritonavir In Patients With Chronic Hepatitis D: Interim Results From The Lonafarnib With Ritonavir In HDV-4 (LOWR HDV-4) Study. HEPATOLOGY, 64, 121A–122A.

Decline in Hepatitis C Virus-related Liver Transplantation Waitlist Registrations among Patients without Hepatocellular Carcinoma: Early Effect of Direct-Acting Antivirals?
Perumpail, R. B., Wong, R. J., Jayasekera, C. R., Gonzalez, S. A., Glenn, J. S., Younossi, Z. M., & Ahmed, A. (2015). Decline in Hepatitis C Virus-related Liver Transplantation Waitlist Registrations among Patients without Hepatocellular Carcinoma: Early Effect of Direct-Acting Antivirals? HEPATOLOGY, 62(6), 1397A.

Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans
Koh, C., Yurdaydin, C., Cooper, S., Cory, D., Dahari, H., Haynes-Williams, V., … Heller, T. (2014). Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans. HEPATOLOGY, 60, 1092A–1093A.

Understanding hepatitis delta virus dynamics and antiviral efficacy of the prenylation inhibitor lonafarnib
Canini, L., Koh, C., Cotler, S., Yurdaydin, C., Cooper, S., Cory, D., … Dahari, H. (2014). Understanding hepatitis delta virus dynamics and antiviral efficacy of the prenylation inhibitor lonafarnib. HEPATOLOGY, 60, 317A.

DIFFERENTIATION OF HUMAN ADIPOSE TISSUE STEM CELLS INTO HEPATOCYTES: ROOM FOR IMPROVEMENT
Lue, J., & Glenn, J. S. (2009). DIFFERENTIATION OF HUMAN ADIPOSE TISSUE STEM CELLS INTO HEPATOCYTES: ROOM FOR IMPROVEMENT. HEPATOLOGY, 50(4), 902A.

HEPATITIS C VIRAL GENOTYPE AGE IS A PREDICTOR OF THE CLINICAL RESPONSE TO INTERFERON THERAPY
Pang, P. S., Planet, P. J., & Glenn, J. S. (2008). HEPATITIS C VIRAL GENOTYPE AGE IS A PREDICTOR OF THE CLINICAL RESPONSE TO INTERFERON THERAPY. HEPATOLOGY, 48(4), 763A.

Membrane association of HCVNS5A: A novel antiviral target.
Elazar, M., Liu, P., Greenberg, H. B., Rice, C. M., & Glenn, J. S. (2001). Membrane association of HCVNS5A: A novel antiviral target. HEPATOLOGY, 34(4), 440A.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
Yurdaydin, C., Abbas, Z., Buti, M., Cornberg, M., Esteban, R., Etzion, O., … Wedemeyer, H. (2019). Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. Journal of Hepatology, 70(5), 1008–15.

A Challenging Case of Triple Hepatitis Virus Infection: An Accurate Diagnostic Test for Hepatitis D Virus Is Urgently Needed
Choudhry, S. A., Reyes, K. J. C., Ishtiaq, R., Aslam, A., Glenn, J. S., & Lau, D. T. Y. (2018). A Challenging Case of Triple Hepatitis Virus Infection: An Accurate Diagnostic Test for Hepatitis D Virus Is Urgently Needed. AMERICAN JOURNAL OF GASTROENTEROLOGY. NATURE PUBLISHING GROUP.

End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection
Etzion, O., Hamid, S. S., Lurie, Y., Gane, E., Bader, N., Yardeni, D., … Apelian, D. (2019). End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. JOURNAL OF HEPATOLOGY, 70, E32.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
Yurdaydin, C., Abbas, Z., Buti, M., Cornberg, M., Esteban, R., Etzion, O., … Hardtke, S. (2019). Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. JOURNAL OF HEPATOLOGY, 70(5), 1008–15.

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection
Townsend, E. C., Zhang, G. Y., Ali, R., Firke, M., Moon, M. S., Han, M. A. T., … Heller, T. (2019). The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 34(4), 764–75.

Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States
Kim, D., Li, A. A., Perumpail, B. J., Gadiparthi, C., Kim, W., Cholankeril, G., … Ahmed, A. (2019). Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. HEPATOLOGY, 69(3), 1064–74.

Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold
Ng, S. S., Saeb-Parsy, K., Blackford, S. J. I., Segal, J. M., Serra, M. P., Horcas-Lopez, M., … Rashid, S. T. (2018). Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold. BIOMATERIALS, 182, 299–311.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection
Tsuge, M., Uchida, T., Walsh, K., Ishida, Y., Tateno, C., Kumar, U., … Chayama, K. (2019). Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. VIRUSES-BASEL, 11(3).

A functional subset of CD8(+) T cells during chronic exhaustion is defined by SIRP alpha expression
Myers, L. M., Tal, M. C., Dulgeroff, L. B. T., Carmody, A. B., Messer, R. J., Gulati, G., … Hasenkrug, K. J. (2019). A functional subset of CD8(+) T cells during chronic exhaustion is defined by SIRP alpha expression. NATURE COMMUNICATIONS, 10.

Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016
Kim, D., Li, A. A., Gadiparthi, C., Khan, M. A., Cholankeril, G., Glenn, J. S., & Ahmed, A. (2018). Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. GASTROENTEROLOGY, 155(4), 1154-+.

Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States
Cholankeril, G., Li, A. A., Cholankeril, R., Toll, A. E., Glenn, J. S., & Ahmed, A. (2018). Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States. JOURNAL OF GENERAL INTERNAL MEDICINE, 33(9), 1423–25.

Pathogenesis of and New Therapies for Hepatitis D
Koh, C., Heller, T., & Glenn, J. S. (2019). Pathogenesis of and New Therapies for Hepatitis D. GASTROENTEROLOGY, 156(2), 461-+.

Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia
Mahale, P., Aka, P., Chen, X., Pfeiffer, R. M., Liu, P., Groover, S., … O'Brien, T. R. (2019). Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia. JOURNAL OF VIRAL HEPATITIS, 26(6), 738–49.

Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.
Kim, D., Adejumo, A. C., Yoo, E. R., Iqbal, U., Li, A. A., Pham, E. A., … Ahmed, A. (2019). Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. Gastroenterology.

HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh, C., Da, B. L., & Glenn, J. S. (2019). HBV/HDV Coinfection: A Challenge for Therapeutics. Clinics in Liver Disease, 23(3), 557–72.

Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis.
Liu, H.-L. L., Lv, J., Zhao, Z.-M. M., Xiong, A.-M. M., Tan, Y., Glenn, J. S., … Liu, C.-H. H. (2019). Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis. Scientific Reports, 9(1), 18719.

CHARACTERIZATION OF HDV, HBsAg AND ALT KINETICS UNDER PEGINTERFERON-LAMBDA MONOTHERAPY: THE PHASE 2 LIMT STUDY
Etzion, O., Duehren, S., Hamid, S. S., Lurie, Y., Gane, E. J., Yardeni, D., … Mawani, M. (2019). CHARACTERIZATION OF HDV, HBsAg AND ALT KINETICS UNDER PEGINTERFERON-LAMBDA MONOTHERAPY: THE PHASE 2 LIMT STUDY. HEPATOLOGY, 70(6), 1496A–1497A.

A PHASE 2 STUDY OF LONAFARNIB, RITONAVIR AND PEGINTERFERON LAMBDA FOR 24 WEEKS: INTERIM END-OF-TREATMENT RESULTS FROM THE LIFT HDV STUDY.
Koh, C., Da, B. L., Surana, P., Huang, A., Kapuria, D., Rotman, Y., … Heller, T. (2019). A PHASE 2 STUDY OF LONAFARNIB, RITONAVIR AND PEGINTERFERON LAMBDA FOR 24 WEEKS: INTERIM END-OF-TREATMENT RESULTS FROM THE LIFT HDV STUDY. HEPATOLOGY, 70(6), 1483A.

Structure of the neurotensin receptor 1 in complex with ß-arrestin 1.
Huang, W., Masureel, M., Qianhui, Q., Janetzko, J., Inoue, A., Kato, H. E., … Kobilka, B. K. (2020). Structure of the neurotensin receptor 1 in complex with ß-arrestin 1. Nature.

PI4KIIIß is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma.
Tan, X., Banerjee, P., Pham, E. A., Rutaganira, F. U., Basu, K., Bota-Rabassedas, N., … Kurie, J. M. (2020). PI4KIIIß is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Science Translational Medicine, 12(527).

COVID-19 and emerging viral infections: The case for interferon lambda.
Prokunina-Olsson, L., Alphonse, N., Dickenson, R. E., Durbin, J. E., Glenn, J. S., Hartmann, R., … Zanoni, I. (2020). COVID-19 and emerging viral infections: The case for interferon lambda. The Journal of Experimental Medicine, 217(5).

2 ' 3 '-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1
Carozza, J., Bohnert, V., Shaw, K., Khanh Nyugen, Skariah, G., Brown, J., … Li, L. (2019). 2 ' 3 '-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. AMER CHEMICAL SOC.

RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look.
Rangan, R., Zheludev, I. N., & Das, R. (2020). RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look. RNA (New York, N.Y.).

Materials science approaches in the development of broad-spectrum antiviral therapies.
Cho, N. J., & Glenn, J. S. (2020). Materials science approaches in the development of broad-spectrum antiviral therapies. Nature Materials.

Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition.
Tal, M. C., Torrez Dulgeroff, L. B., Myers, L., Cham, L. B., Mayer-Barber, K. D., Bohrer, A. C., … Hasenkrug, K. J. (2020). Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition. MBio, 11(3).

High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California.
Fong, T.-L., Lee, B. T., Chang, M., Nasanbayar, K., Tsogtoo, E., Boldbaatar, D., … Saito, T. (2020). High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California. Digestive Diseases and Sciences.

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., … Baric, R. S. (2020). A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature.

Progenitor identification and SARS-CoV-2 infection in human distal lung organoids.
Salahudeen, A. A., Choi, S. S., Rustagi, A., Zhu, J., van Unen, V., de la O, S. M., … Kuo, C. J. (2020). Progenitor identification and SARS-CoV-2 infection in human distal lung organoids. Nature.

Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., … Baric, R. S. (2021). Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature.

Extracellular Matrix Functionalization and Huh-7.5 Cell Coculture Promote the Hepatic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells in a 3D ICC Hydrogel Scaffold.
Wang, Y., Lee, J.-H. H., Shirahama, H., Seo, J., Glenn, J. S., & Cho, N.-J. J. (2016). Extracellular Matrix Functionalization and Huh-7.5 Cell Coculture Promote the Hepatic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells in a 3D ICC Hydrogel Scaffold. ACS Biomaterials Science & Engineering, 2(12), 2255–2265.

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
Feld, J. J., Kandel, C., Biondi, M. J., Kozak, R. A., Zahoor, M. A., Lemieux, C., … Hansen, B. E. (2021). Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. The Lancet. Respiratory Medicine.

Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity
Carozza, J. A., Bohnert, V., Nguyen, K. C., Skariah, G., Shaw, K. E., Brown, J. A., … Li, L. (2020). Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity. NATURE CANCER, 1(2), 184-+.

Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity.
Carozza, J. A., Böhnert, V., Nguyen, K. C., Skariah, G., Shaw, K. E., Brown, J. A., … Li, L. (2020). Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity. Nature Cancer, 1(2), 184–196.

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.
Jagannathan, P., Andrews, J. R., Bonilla, H., Hedlin, H., Jacobson, K. B., Balasubramanian, V., … Singh, U. (2021). Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nature Communications, 12(1), 1967.

Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination.
Lopez Angel, C. J., Pham, E. A., Du, H., Vallania, F., Fram, B. J., Perez, K., … Furman, D. (2021). Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. Proceedings of the National Academy of Sciences of the United States of America, 118(14).

Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy.
Hercun, J., Kim, G. E., Da, B. L., Rotman, Y., Kleiner, D. E., Chang, R., … Heller, T. (2021). Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy. Alimentary Pharmacology & Therapeutics.

Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells.
Shi, L., Tan, X., Liu, X., Yu, J., Bota-Rabassedas, N., Niu, Y., … Kurie, J. M. (2021). Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 118(25).

Cryo-EM and antisense targeting of the 28-kDa frameshift stimulation element from the SARS-CoV-2 RNA genome.
Zhang, K., Zheludev, I. N., Hagey, R. J., Haslecker, R., Hou, Y. J., Kretsch, R., … Das, R. (2021). Cryo-EM and antisense targeting of the 28-kDa frameshift stimulation element from the SARS-CoV-2 RNA genome. Nature Structural & Molecular Biology.

HEPATITIS D VIRUS INFECTION IN UNITED STATES WOMEN WITH OR AT RISK FOR HIV
Argirion, I., Mahale, P., Kuniholm, M. H., Pfeiffer, R., Koshiol, J., Glenn, J., & O'Brien, T. R. (2021). HEPATITIS D VIRUS INFECTION IN UNITED STATES WOMEN WITH OR AT RISK FOR HIV. HEPATOLOGY. WILEY.

A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
Yurdaydin, C., Keskin, O., Yurdcu, E., Caliskan, A., Onem, S., Karakaya, F., … Glenn, J. S. (2021). A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology (Baltimore, Md.).

Combination of Novel Therapies for HDV.
Elazar, M., & Glenn, J. S. (2022). Combination of Novel Therapies for HDV. Viruses, 14(2).

Hepatitis Delta Virus Testing and Research.
Glenn, J. S. (2021). Hepatitis Delta Virus Testing and Research. Gastroenterology & Hepatology, 17(10), 482–484.

Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial.
Hassanein, T., Tai, D., Liu, C., Box, T. D., Tong, M. J., Rossaro, L., … Vierling, J. M. (2022). Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial. Evidence-Based Complementary and Alternative Medicine : ECAM, 2022, 4494099.

A Phase 2 Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study
Koh, C., Hercun, J., Rahman, F., Huang, A., Da, B., Surana, P., … Heller, T. (2020). A Phase 2 Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study. JOURNAL OF HEPATOLOGY. ELSEVIER.

Lonafarnib combination with peginterferon Lambda diminished triphasic HDV kinetic pattrn seen under Lambda monotherapy: the LIFT HDV study
Duehren, S., Koh, C., Hercun, J., Rahman, F., Surana, P., Vittal, A., … Heller, T. (2022). Lonafarnib combination with peginterferon Lambda diminished triphasic HDV kinetic pattrn seen under Lambda monotherapy: the LIFT HDV study. JOURNAL OF HEPATOLOGY. ELSEVIER.

Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States
Wong, R., Brosgart, C., Wong, S., Feld, J., Glenn, J., Hamid, S. S., … Gish, R. G. (2022). Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States. JOURNAL OF HEPATOLOGY. ELSEVIER.

Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMT-1 study
Cardozo-Ojeda, E. F., Duehren, S., Hamid, S. S., Lurie, Y., Gane, E. J., Nevo-Shor, A., … Etzion, O. (2022). Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMT-1 study. JOURNAL OF HEPATOLOGY. ELSEVIER.

Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.
Hagey, R. J., Elazar, M., Pham, E. A., Tian, S., Ben-Avi, L., Bernardin-Souibgui, C., … Glenn, J. S. (2022). Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2. Nature Medicine.

Programmable antivirals to target conserved essential shapes in pandemic viral genomes
Glenn, J. S. (2022). Programmable antivirals to target conserved essential shapes in pandemic viral genomes. NATURE MEDICINE.

First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer.
Csiki, I., Dong, A., Tuan, B. Y., John, E., O'Toole, L., Seppa, J., … Klumpp, K. (2022). First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients
Mhlanga, A., Zakh, R., Churkin, A., Reinharz, V., Glenn, J. S., Etzion, O., … Dahari, H. (2022). Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients. MATHEMATICS, 10(20).

FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA
Yurdaydin, C., Yurdcu, E., Gumussoy, M., Keskin, O., Gencdal, G., Akyildiz, M., … Glenn, J. (2022). FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA. HEPATOLOGY. WILEY.

ESTIMATING THE PREVALENCE OF CHRONIC HEPATITIS B AMONG FOREIGN-BORN PERSONS LIVING IN CANADA BY COUNTRY OF ORIGIN
Wong, R. J., Brosgart, C. L., Wong, S. S., Feld, J. J., Hirode, G., Glenn, J., … Gish, R. G. (2022). ESTIMATING THE PREVALENCE OF CHRONIC HEPATITIS B AMONG FOREIGN-BORN PERSONS LIVING IN CANADA BY COUNTRY OF ORIGIN. HEPATOLOGY. WILEY.

ESTIMATING HEPATITIS DELTA PREVALENCE AMONG HIGH RISK POPULATIONS IN THE UNITED STATES: A SYSTEMATIC REVIEW
Wong, R. J., Brosgart, C. L., Wong, S. S., Feld, J. J., Glenn, J., Moraras, K., … Gish, R. G. (2022). ESTIMATING HEPATITIS DELTA PREVALENCE AMONG HIGH RISK POPULATIONS IN THE UNITED STATES: A SYSTEMATIC REVIEW. HEPATOLOGY. WILEY.

Programmable Antivirals and Just-in-Time Vaccines: Biosecurity Implications of Viral RNA Secondary Structure Targeting.
Pannu, J., & Glenn, J. S. (2022). Programmable Antivirals and Just-in-Time Vaccines: Biosecurity Implications of Viral RNA Secondary Structure Targeting. Health Security.

Early Treatment with Pegylated Interferon Lambda for Covid-19.
Reis, G., Moreira Silva, E. A., Medeiros Silva, D. C., Thabane, L., Campos, V. H., Ferreira, T. S., … Glenn, J. S. (2023). Early Treatment with Pegylated Interferon Lambda for Covid-19. The New England Journal of Medicine, 388(6), 518–528.

Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial.
Etzion, O., Hamid, S., Lurie, Y., Gane, E. J., Yardeni, D., Duehren, S., … Glenn, J. (2023). Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial. Hepatology (Baltimore, Md.).

Pegylated Interferon Lambda for Covid-19. Reply.
Reis, G., Mills, E. J., & Glenn, J. S. (2023). Pegylated Interferon Lambda for Covid-19. Reply. The New England Journal of Medicine, 388(22), 2108.